Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mecro System is a South Korean biotechnology company specializing in microfluidic-based molecular diagnostic systems. The company develops ultra-fast PCR (Polymerase Chain Reaction) platforms and lab-on-a-chip technologies designed for point-of-care testing (POCT). Their core product line includes the Mecro-PCR system, which enables rapid and accurate detection of infectious diseases such as COVID-19 and influenza. By integrating complex laboratory processes into compact, disposable cartridges, Mecro System provides decentralized diagnostic solutions for clinics and hospitals. The company's proprietary technology significantly reduces thermal cycling times, allowing for results in under 20 minutes without sacrificing sensitivity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mecro System.